International Stem Cell Corporation (ISCO) Leads while Regenerative Medicine Becomes a Global Interest
A publicly-traded biotech company, International Stem Cell Corporation (OTCQB: ISCO) focuses its efforts toward developing innovative solutions that advance the field of regenerative medicine. This field strives to create functional tissue to repair and replace tissue or organs that have lost their function due to damage, disease, age, and congenital defects. ISCO has contributed to regenerative science by developing its own novel stem cell technology called parthenogenesis, which uses unfertilized eggs and addresses immune-rejection among humans. Stem cells have the potential to divide and differentiate themselves into any cell type. This means that these cells can treat degenerative diseases of the eye, nervous system, and liver through rebuilding and regeneration. Technological advancement in tissue engineering and stem cell therapy is expected to drive the global market for regenerative medicine.
Parthenogenesis uniquely studies immune-rejection, cell differentiation, and DNA patterns. ISCO’s technology creates a whole new class of stem cells called human parthenogenetic stem cells (hpSC). These are created by stimulating the oocytes (unfertilized eggs) into dividing. Different oocyte activation techniques create either heterozygous human parthenogenetic stem cell lines or homozygous human parthenogenetic stem cell lines. The former cells are only compatible with their donors, while the latter could be compatible with a large portion of the population. To maximize this innovative technology, the company developed the first collection of non-embryonic histocompatible (human compatible) stem cells used for research or commercial purposes. ISCO’s cell lines have the possibility of treating millions of people around the world.
Immune-matching, histocompatible cells have the potential of treating and even preventing diseases worldwide. For example, cancer is thought to come from abnormal cell proliferation and differentiation. Using stem cells, scientists can map out the human development of cells to see how cancer starts while also discovering treatments and prevention. Other diseases like Alzheimer’s and Parkinson’s could be treated using healthy cells to replace damaged ones. This is an exciting time for stem cell research because of the positive impact it could have around the globe.
To showcase increasing interest in their groundbreaking developments, ISCO recently announced that negotiations between two healthcare institutes and the company’s management have begun surrounding private placement of $6.3 million of the company’s convertible preferred stock and common stock purchase warrants to purchase $25.7 million of the company’s common stock. With exposure and interest surrounding regenerative medicine steadily increasing worldwide, ISCO is strongly poised to further its scientific studies as successful contributors in the field.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
A publicly-traded biotech company, International Stem Cell Corporation (OTCQB: ISCO) focuses its efforts toward developing innovative solutions that advance the field of regenerative medicine. This field strives to create functional tissue to repair and replace tissue or organs that have lost their function due to damage, disease, age, and congenital defects. ISCO has contributed to regenerative science by developing its own novel stem cell technology called parthenogenesis, which uses unfertilized eggs and addresses immune-rejection among humans. Stem cells have the potential to divide and differentiate themselves into any cell type. This means that these cells can treat degenerative diseases of the eye, nervous system, and liver through rebuilding and regeneration. Technological advancement in tissue engineering and stem cell therapy is expected to drive the global market for regenerative medicine.
Parthenogenesis uniquely studies immune-rejection, cell differentiation, and DNA patterns. ISCO’s technology creates a whole new class of stem cells called human parthenogenetic stem cells (hpSC). These are created by stimulating the oocytes (unfertilized eggs) into dividing. Different oocyte activation techniques create either heterozygous human parthenogenetic stem cell lines or homozygous human parthenogenetic stem cell lines. The former cells are only compatible with their donors, while the latter could be compatible with a large portion of the population. To maximize this innovative technology, the company developed the first collection of non-embryonic histocompatible (human compatible) stem cells used for research or commercial purposes. ISCO’s cell lines have the possibility of treating millions of people around the world.
Immune-matching, histocompatible cells have the potential of treating and even preventing diseases worldwide. For example, cancer is thought to come from abnormal cell proliferation and differentiation. Using stem cells, scientists can map out the human development of cells to see how cancer starts while also discovering treatments and prevention. Other diseases like Alzheimer’s and Parkinson’s could be treated using healthy cells to replace damaged ones. This is an exciting time for stem cell research because of the positive impact it could have around the globe.
To showcase increasing interest in their groundbreaking developments, ISCO recently announced that negotiations between two healthcare institutes and the company’s management have begun surrounding private placement of $6.3 million of the company’s convertible preferred stock and common stock purchase warrants to purchase $25.7 million of the company’s common stock. With exposure and interest surrounding regenerative medicine steadily increasing worldwide, ISCO is strongly poised to further its scientific studies as successful contributors in the field.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
